|Day Low/High||259.56 / 261.22|
|52 Wk Low/High||98.02 / 230.77|
Bio-Reference Labs CEO Dr. Marc Grodman says the Supreme Court ruling against human gene patents means big things for the testing industry.
The fear of 'dead money' has brought Quest back to an extremely low-risk entry point.
This is one of the few stocks still trading at a bargain valuation.
Selling even a full year costs nothing except the opportunity to move on quickly to the next trade.
A snap-back in the shares is almost certain from these very depressed levels.
I challenge you to find any value in this coverage of LabCorp.
Over the past dozen years every significant pullback has been an opportunity to buy.